Bluejay Diagnostics, Inc.
BJDXHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeBluejay Diagnostics, Inc. operates as a medical diagnostics company. With a market capitalization of $2.6M, it sits in micro-cap territory. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.
Market Cap
$2.6M
Beta
0.89
P/E (TTM)
—
P/E (Fwd)
-1.83
EPS (TTM)
$-3.33
EPS (Fwd)
$-0.32
ROE
-98.9%
ROA
-51.1%
Cash
$9.6M
Total Debt
$80,670
Free CF
-$3.5M
52W Change
-93.7%
Annual Financials
Cash vs Debt
Where BJDX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BJDX finished 59.30% below its 150-day moving average ($1.72) and 63.92% below its 200-day moving average ($1.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BJDX overbought or oversold?
At the October 20, 2026 close, BJDX's RSI(14) was 23.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $9.6M in cash and $81K in debt, BJDX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$3.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -98.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $249K (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, BJDX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BJDX.